AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk quarterly results, drug development, AI integration, ...
AstraZeneca Plc on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when ...
With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight ...
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk quarterly results, drug development, AI integration, ...
The approval relies on positive data from the POTOMAC Phase III trial.
AstraZeneca and Daiichi Sankyo received FDA approval for Enhertu in early-stage HER2-positive breast cancer in both ...
AstraZeneca (AZN) climbed 3.1% as Bernstein reaffirms outperform rating, citing non-oncology portfolio as undervalued driver ...
Bloomberg on MSN
AstraZeneca broadens US growth push
AstraZeneca CFO Aradhana Sarin discusses how the pharmaceutical company is broadening its US shareholder base and plans to ...
Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer ...
View AstraZeneca PLC AZN stock quote prices, financial information, real-time forecasts, and company news from CNN.
By Bhanvi Satija LONDON, May 18 (Reuters) - Anglo-Swedish drugmaker AstraZeneca said on Monday its hypertension pill baxdrostat had been approved in the United States, offering a new treatment option ...
The U.K. drugmaker recently direct-listed its shares in the U.S., betting on a new-drug pipeline to achieve its revenue target by 2030.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results